Hero saves, is killed by his security force
Blog
Heroes
Remember there names. They tried to warn you.
“You may know the names of these antiwar conservatives. Some are famous: Patrick Buchanan and Robert Novak. Others are not: Llewellyn Rockwell, Samuel Francis, Thomas Fleming, Scott McConnell, Justin Raimondo, Joe Sobran, Charley Reese, Jude Wanniski, Eric Margolis, and Taki Theodoracopulos.”
From “Unpatriotic Conservatives” by David Frum. More here
The Antiwar Comic: The Distraction
How am I not a Centrist if I’m always in the middle of this?
For more comics visit The Webcomic Factory.
Can Bitcoin Be Palestine’s Currency Of Freedom?
“Independence is financial,” Abukhdeir told me. “If we don’t have financial freedom, nothing is going to change.”
But how do Palestinians buy bitcoin? “We always find the holes,” Abuwedad said.
More here
U.S. Senators Propose National Guard Taiwan Partnership
The Antiwar Comic: The Broken Gauge
Media bad, war bad. Not that anyone remembers history except maybe you guys.
Check out more comics at the Webcomic Factory.
Sam Colt: The Forgotten History of America’s Legendary Firearms Inventor and Manufacturer
Born on July 19, 1814, in Hartford, Connecticut, Samuel Colt played a vital role in American culture and folklore. The inventor and creator of the first handheld revolver, Sam Colt made it possible to have a handgun that could fire rapidly without needing to be reloaded after every shot. Known as the great equalizer, it’s been said that “Abe Lincoln may have freed all men, but Sam Colt made them equal.”
Colt’s knack for inventing and his passion for firearms paved the way for the American fascination with guns. Some would argue that it’s because of Samuel Colt (and his shrewd business and advertising sense) that Colt became a household name, both during his lifetime and now, 200 years after his birth.
More here at ammo.com
Forever Soldiers To Fight Forever Wars
The U.S. military says it is months away from launching clinical trials of a pill designed to block or reduce many degenerative effects of aging—an oral treatment that a leading researcher in the field says is better than nothing while questioning how effective it will ultimately prove.
U.S. Special Operations Command (SOCOM)—which develops and employs Special Operations Forces worldwide to advance U.S. policies and objectives—has “completed preclinical safety and dosing studies in anticipation of follow-on performance testing” of a first-in-class nicotinamide adenine dinucleotide, oxidized state (NAD+) enhancer, a small molecule drug being developed by Metro International Biotech (MetroBiotech), Navy Cmdr. Timothy A. Hawkins, a spokesperson for SOCOM, told GEN.
SOCOM and MetroBiotech are set to start clinical trials during the 2022 federal fiscal year, which starts October 1.
“If the preclinical studies and clinical trials bear out, the resulting benefits include improved human performance, such as increased endurance and faster recovery from injury,” Hawkins said.
“This effort in particular is about enhancing the mission readiness of our forces by improving performance characteristics that typically decline with age,” Hawkins explained. “These efforts are not about creating physical traits that don’t already exist naturally.”
The SOCOM testing is among studies being carried out to assess MetroBiotech’s lead candidate, David J. Livingston, PhD, MetroBiotech’s president and CSO, told GEN. “I can confirm that we and our clinical partners have completed multiple Phase I human safety trials of a lead molecule,” Livingston said. “Metro has also initiated exploratory Phase II studies in several areas of therapeutic application, including the treatment of rare diseases, diseases of aging, and in collaboration with SOCOM, studies on the effects of our compounds on muscle energetics and human performance.” Livingston said MetroBiotech won’t discuss details of its clinical trials in advance of future postings on ClinicalTrials.gov or joint publications of clinical data.
Potential to “truly delay aging”
SOCOM has spent $2.8 million on its anti-aging effort since it began in 2018, Hawkins said.
Lisa R. Sanders, director of science and technology for Special Operations Forces, Acquisition, Technology, & Logistics, said during a virtual conference last month that SOCOM was able to fund its anti-aging testing through Other Transaction Authority (OTA) funds and Middle Tier Acquisition authority, created in 2015 to enable rapid acquisitions designed to deliver capabilities within 2–5 years.
“This small molecule has the potential, if it is successful, to truly delay aging [and] truly prevent onset of injury, which is just amazingly game-changing,” Sanders said, addressing “Assisting the Modern Warfighter,” a featured session held as part of the Defense One Defense Tech Summit, held June 21–25.
More here at Genetic And Engineering News
Podcasts
